agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.
Relapsed/Refractory Multiple Myeloma
DRUG: agenT-797
Number Of Participants With Treatment-related Adverse Events, This will be determined by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0., Baseline through Day 28 post cell infusion|Number Of Dose-limiting Toxicities, Baseline through Day 14 post cell infusion
Persistence Of agenT-797 In Peripheral Blood, Baseline/Day 1 (pre-infusion, 5 minutes, 0.25, 0,5, 1, 2, and 4 hours post cell infusion), Days 2, 3, 5, 8, 15, 22, and 29, Weeks 6, 8, and 12, and Months 6, 9, and 12|Overall Response Rate (ORR), End of study visit (up to 12 months)|Duration Of Response (DOR), End of study visit (up to 12 months)|Duration Of Clinical Benefit, End of study visit (up to 12 months)|Time To Response (TTR), End of study visit (up to 12 months)|Measurement Of Serum Alloantibodies To Major Histocompatibility Complex Class I And II, Baseline/Day 1 (pre-infusion), Day 22, Week 6, and end of study visit (up to 12 months)
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.